Kobayashi Takeshi, Akiyama Hideki
Divisions of Hematology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Gan To Kagaku Ryoho. 2009 Mar;36(3):351-6.
The method and way of hematopoietic stem cell transplantation have been expanded and become complex recently. We discussed recent progress in this field, mainly in the treatment of leukemia. The first topic is the new arrival of the tyrosine kinase inhibitor, imatinib. Imatinib dramatically changed the treatment strategies for chronic myeloid leukemia. The same drug is now changing the treatment options and indications of hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Efforts have also been made to expand the cell source for transplantation to cord blood and haploidentical donors. Almost 5,000 patients have undergone cord blood transplantation in Japan. Finally, the results of reduced-intensity stem cell transplantation may well expand the patient population eligible for transplantation.
造血干细胞移植的方法和途径近来已得到扩展且变得复杂。我们讨论了该领域的最新进展,主要是在白血病治疗方面。第一个主题是酪氨酸激酶抑制剂伊马替尼的新应用。伊马替尼极大地改变了慢性髓性白血病的治疗策略。现在,同一药物正在改变费城染色体阳性急性淋巴细胞白血病患者造血干细胞移植的治疗选择和适应症。人们还努力将移植的细胞来源扩展到脐血和单倍体相合供体。在日本,近5000名患者接受了脐血移植。最后,减低强度干细胞移植的结果很可能会扩大适合移植的患者群体。